Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC)
Standard
Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC) : a study from the Tumor Bank Ovarian Cancer (TOC) Consortium. / Guan, Jun; Darb-Esfahani, Silvia; Richter, Rolf; Taube, Eliane T; Ruscito, Ilary; Mahner, Sven; Woelber, Linn; Prieske, Katharina; Concin, Nicole; Vergote, Ignace; Van Nieuwenhuysen, Els; Achimas-Cadariu, Patriciu; Glajzer, Joanna; Woopen, Hannah; Stanske, Mandy; Kulbe, Hagen; Denkert, Carsten; Sehouli, Jalid; Braicu, Elena Ioana.
in: J CANCER RES CLIN, Jahrgang 145, Nr. 4, 04.2019, S. 1063-1073.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC)
T2 - a study from the Tumor Bank Ovarian Cancer (TOC) Consortium
AU - Guan, Jun
AU - Darb-Esfahani, Silvia
AU - Richter, Rolf
AU - Taube, Eliane T
AU - Ruscito, Ilary
AU - Mahner, Sven
AU - Woelber, Linn
AU - Prieske, Katharina
AU - Concin, Nicole
AU - Vergote, Ignace
AU - Van Nieuwenhuysen, Els
AU - Achimas-Cadariu, Patriciu
AU - Glajzer, Joanna
AU - Woopen, Hannah
AU - Stanske, Mandy
AU - Kulbe, Hagen
AU - Denkert, Carsten
AU - Sehouli, Jalid
AU - Braicu, Elena Ioana
PY - 2019/4
Y1 - 2019/4
N2 - OBJECTIVE: The impact of angiogenesis on long-term survival of high-grade serous ovarian cancer (HGSOC) patients remains unclear. This study investigated whether angiogenic markers correlated with 5-year progression-free survival (PFS) in a large cohort of matched advanced HGSOC tissue samples.METHODS: Tumor samples from 124 primary HGSOC patients were retrospectively collected within the Tumor Bank Ovarian Cancer ( http://www.toc-network.de ). All patients were in advanced stages (FIGO stage III-IV). No patient had received anti-angiogenesis therapy. The cohort contains 62 long-term survivors and 62 controls matched by age and post-surgical tumor residuals. Long-term survivors were defined as patients with no relapse within 5 years after the end of first-line chemotherapy. Controls were patients who suffered from first relapse within 6-36 months after primary treatment. Samples were assessed for immunohistochemical expression of vascular endothelial growth factor (VEGF) A and VEGF receptor 2 (VEGFR2). Expression profiles of VEGFA and VEGFR2 were compared between the two groups.RESULTS: Significant correlation between VEGFA and VEGFR2 expression was observed (p < 0.0001, Spearman coefficient 0.347). A high expression of VEGFR2 (VEGFR2high) was found more frequently in long-term survivors (77.4%, 48/62) than in controls (51.6%, 30/62, p = 0.001), independent of FIGO stage and VEGFA expression in multivariate analysis (p = 0.005). Also, VEGFR2high was found the most frequently in women with PFS ≥ 10 years (p = 0.001) among all 124 patients. However, no significant association was detected between VEGFA expression and 5-year PFS (p = 0.075).CONCLUSIONS: VEGFR2 overexpression significantly correlated with long-term PFS in HGSOC patients, independent of age, FIGO stage, tumor residual and VEGFA expression.
AB - OBJECTIVE: The impact of angiogenesis on long-term survival of high-grade serous ovarian cancer (HGSOC) patients remains unclear. This study investigated whether angiogenic markers correlated with 5-year progression-free survival (PFS) in a large cohort of matched advanced HGSOC tissue samples.METHODS: Tumor samples from 124 primary HGSOC patients were retrospectively collected within the Tumor Bank Ovarian Cancer ( http://www.toc-network.de ). All patients were in advanced stages (FIGO stage III-IV). No patient had received anti-angiogenesis therapy. The cohort contains 62 long-term survivors and 62 controls matched by age and post-surgical tumor residuals. Long-term survivors were defined as patients with no relapse within 5 years after the end of first-line chemotherapy. Controls were patients who suffered from first relapse within 6-36 months after primary treatment. Samples were assessed for immunohistochemical expression of vascular endothelial growth factor (VEGF) A and VEGF receptor 2 (VEGFR2). Expression profiles of VEGFA and VEGFR2 were compared between the two groups.RESULTS: Significant correlation between VEGFA and VEGFR2 expression was observed (p < 0.0001, Spearman coefficient 0.347). A high expression of VEGFR2 (VEGFR2high) was found more frequently in long-term survivors (77.4%, 48/62) than in controls (51.6%, 30/62, p = 0.001), independent of FIGO stage and VEGFA expression in multivariate analysis (p = 0.005). Also, VEGFR2high was found the most frequently in women with PFS ≥ 10 years (p = 0.001) among all 124 patients. However, no significant association was detected between VEGFA expression and 5-year PFS (p = 0.075).CONCLUSIONS: VEGFR2 overexpression significantly correlated with long-term PFS in HGSOC patients, independent of age, FIGO stage, tumor residual and VEGFA expression.
KW - Cancer Survivors
KW - Cystadenocarcinoma, Serous/blood supply
KW - Female
KW - Humans
KW - Immunohistochemistry
KW - Middle Aged
KW - Neoplasm Staging
KW - Ovarian Neoplasms/blood supply
KW - Progression-Free Survival
KW - Vascular Endothelial Growth Factor A/biosynthesis
KW - Vascular Endothelial Growth Factor Receptor-2/biosynthesis
U2 - 10.1007/s00432-019-02877-4
DO - 10.1007/s00432-019-02877-4
M3 - SCORING: Journal article
C2 - 30810838
VL - 145
SP - 1063
EP - 1073
JO - J CANCER RES CLIN
JF - J CANCER RES CLIN
SN - 0171-5216
IS - 4
ER -
